Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: Its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities

Journal of Medicinal Chemistry

Volumn 41, Issue 6, 1998, Pages 894-901

  Bierer, Donald E ^a,b  

^a Shaman Pharmaceuticals Inc   (United States)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CRYPTOLEPINE; CRYPTOLEPINE DERIVATIVE; HERBACEOUS AGENT; METFORMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG ISOLATION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

3T3 CELLS; ADIPOSE TISSUE; ALKALOIDS; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; EATING; FRUCTOSE; GLUCOSE; HYPOGLYCEMIC AGENTS; INDOLES; MALE; MICE; MICE, OBESE; PLANT EXTRACTS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 15444342885     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9704816     Document Type: Article

References (63)

1. Bierer, D. E.; Carlson, T. J.; King, S. R. Integrating Indigenous Knowledge, Tropical Medicinal Plants, Medicine, Modern Science, and Reciprocity into a Novel Drug Discovery Approach. Network Sci. 1996,2 (No. 5) (http://www.awod.com/netsci/Issues/
2. May96/feature2.html).
3. Carlson, T. J.; Cooper, R.; King, S. R.; Rozhon, E. J. Modern Science and Traditional Healing. In Phytochemical Diversity; Wrigley, S., Hayes, M., Thomas, R., Crystal, E., Eds.; Royal Society of Chemistry: London, 1997; pp 84-95.
4. Oubré, A. Y.; Carlson, T. J.; King, S. R.; Reaven, G. M. From Plant to Patient: An Ethnobotanical Approach to the Identification of New Drugs for the Treatment of NIDDM. Diabetologia 1997, 40, 614-617.
5. Much of the literature reports C. sanguinolenta being a member of the Asclepiadaceae family (see ref 5); however, some of the literature reports that Cryptolepis sp. are members of the Periplocaceae family. \Vhile some botanists consider the Periplocaceae a separate family from the Asclepiadaceae (see ref 6), this position is somewhat controversial. At this point, C. sanguinolenta may more correctly be considered to be a member of the subfamily Periplocoideae of the Asclepiadaceae family (see refs 7 and 8).
6. Hutchinson, J.; Dalziel, J. M. Flora of West Tropical Africa; The Crown Agents for the Colonies: London, 1931; Vol. II, Part l, p 53.
7. Hutchinson, J. The Families of Flowering Plants; Clarendon Press: Oxford, 1973; pp 471-474.
8. Cronquist, A. An Integrated System of Classification of Flowering Plants; Columbia University Press: New York, 1981; pp.879'882.
9. Omlor, R. Do Menabea venenata and Secamonopsis madagascariensis Represent Missing Links Between Periplocaceae, Secamonoideae and Marsdenieae (Asclepiadaceae)? Kew Bull. 1996, 51 (4), 695-715.
10. Gomes, E. T.; Diniz, M. A. Plantas usadas em medicina tradicional na regiäno de Contuboel. (Plants used in Traditional Medicine from the Contuboel Region (of Guinea-Bissau).) Communicaçoes JICT - Série das Ciências Agrârias 1993,13, 153165.
11. Diniz, M. A.; Silva, O.; Paulo, M. A.; Gomes, E. T. In The Biodiversity of African Plants; van der Maesen, L. J. G., van der Burgt, X. M., van der Medenbach de Rooy, J. M., Eds.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 1996; pp 727-731.
12. Feijao, R. O. In Elucidario Fitologico; Instituto Botanico de Lisboa: Lisbon, 1961; Vol. 2, p 258.
13. Suva, O.; Duarte, A.; Cabrita, J.; Pimentel, M.; Diniz, A.; Gomes, E. T. Antimicrobial Activity of Guinea-Bissau Traditional Remedies. J. Ethnopharmacol. 1996, 50, 55-59.
14. Oliver-Bever, B. E. P. Medicinal Plants in Tropical West Africa; Cambridge University Press: Cambridge, 1986; pp 18,41, 131.
15. Watt, J. M.; Breyer-Brandwijk, M. G. The Medicinal and Poisonous Plants of Southern and Eastern Africa; E.&S. Livingstone Ltd.: Edinburgh, 1962; pp 128-129.
16. Boakye-Yiadom, K. Antimicrobial Properties of Some West African Plants. Quart. J. Crude Drug Res. 1979, 17, 78-80.
17. Boye, G. L.; Ampofo, O. In Proceeding of the First International Symposium on Cryptolepine; Boakye-Yiadom, K., Bamgbose, S. O. A., Eds.; University of Science and Technology: Ghana, 1983; pp 37-40.
18. Boye, G. L. Antimalarial Action of Cryptolepis sanguinolenta Extract. Proceedings of the International Symposium on EastWest Medicine, Oct. 10-11, 1989, Seoul, Korea; 1990, pp 243251.
19. Analytical quantification of the aqueous extract administered to indigenous humans revealed that the dose corresponded to 0.11 mg/kg/day cryptolepine.
20. Results of a human study conducted in Ghana on an aqueous extract administered to NIDDM patients will be published 'elsewhere. See: Luo, J.; Fort, D. M.; Carlson, T. J.; Noamesi, B.; nii-Amon-Kotei, D.; King, S. R.; Tsai, J.; Quan, J.; Hobensack, C.; Lapresca, P.; Waldeck, N.; Mendez, C. D.; Jolad, S. D.; Bierer, D. E.; Reaven, G. M. Cryptolepine, A Potentially Useful New Antihyperglycemic Agent Isolated from Cryptolepis sanguinolenta: An Example of the Ethnobotanical Approach to Drug Discovery. Diabetic Med. 1998, in press.
21. Fichter, F.; Boehringer, R. Ueber Chindolin. (Over Quindoline.) Chem. Ber. 1906, 39, 3932-3942.
22. Fichter, F.; Probst, H. Zur Kenntnis des Methyl-chindolanols. (To the Knowledge of the Methyl-Quindolanols.) Chem. Ber. 1907,40, 3478.
23. Fichter, F.; Rohner, F. Über einige Derivate des Chindolins. (About A Quindoline Derivative.) Chem. Ber. 1910, 43, 3489-3499.
24. Clinquart, E. Sur la composition chimique de Cryptolepis triangularis, plante congolaise. (On thé Chemical Composition of Cryptolepis triangularis, Plants from the (Belgian) Congo.) Bull. Acad. R. Med. Belg. 1929, 9, 627-635.
25. Delvaux, E. Sur la Cryptolépine. (On Cryptolepine.) J. Pharm. Belg. 1931, 13, 955-959.
26. Delvaux, E. Sur la Cryptolépine. (On Cryptolepine.) J. Pharm. Belg. 1931,13, 973-977.
27. 2, was first isolated as a purple solid (mp 175-178 °C) by Gellért in 1951 from C. sanguinolenta. Gellért assigned the structure of 1 to cryptolepine, a compound which had previously been synthesized in 1906 by Fichter and Boehringer.
28. Gellért, E.; Raymond-Hamet; Schiittier, E. Die Konstitution des Alkaloids Cryptolepin. (The Constitution of the Alkaloid Cryptolepine.) Helv. Chim. Acta 1951, 34, 642-651.
29. Dwuma-Badu, D.; Ayim, J. S. K.; Fiagbe, F. N. I. Y.; Knapp, J. E.; Schiff, P. L., Jr.; Slatkin, D. J. Constituents of West African Medicinal Plants XX: Quindoline from Cryptolepis sanguinolenta. J. Pharm. Sci. 1978, 67, 433-434.
30. 13C-NMR Assignments of Cryptolepine, A 3:4Benz-δ-carboline Derivative Isolated from Cryptolepis sanguinolenta. Planta Med. 1990, 56, 416-417.
31. Gunatilaka, A. A. L.; Sotheeswaran, S.; Balasubramaniam, S.; Chandrasekara, A. L; Sriyani, H. T. B. Studies on Medicinal Plants of Sri Lanka. Planta Med. 1980, 39, 66-72.
32. Boakye-Yiadom, K. In Proceeding of the First International Symposium on Cryptolepine; Boakye-Yiadom, K., Bamgbose, S. O. A., Eds.; University of Science and Technology: Ghana, 1983; pp 57-64.
33. Cimanga, K; Pieters, L.; Claeys, M.; Vanden Berghe, D.; Vlietinck, A. J. Biological Activities of Cryptolepine. An Alkaloid from Cryptolepis sanguinolenta. Planta Med. 1991, 57 (Suppl. 2), A98-A99.
34. Boakye-Yiadom, K; Heman-Ackah, S. M. Cryptolepine Hydrochloride Effect on Staphlococcus aureus. J. Pharm. Sci. 1979, 68, 1510-1514.
35. Paulo, A.; Pimentel, M.; Viegas, S.; Pires, I.; Duarte, A.; Cabrita, J.; Gomes, E. T. Cryptolepis sanguinolenta Activity Against Diarrhoeal Bacteria J. Ethnopharmacol. 1994, 44, 73-77.
36. Cimanga, K; De Bruyne, T.; Lasure, A.; Van Poel, B.; Pieters, L.; Claeys, M.; Vanden Berghe, D.; Kambu, K.; Tona, L.; Vlietinck, A. J. In Vitro Biological Activities of Alkaloids from Cryptolepis sanguinolenta. Planta Med. 1996, 62, 22-27.
37. Paulo, A.; Duarte, A.; Gomes, E. T. In Vitro Antibacterial Screening of Cryptolepis sanguinolenta alkaloids. J. Ethnopharmacol. 1994, 44, 127-130.
38. Bamgbose, S. O. A.; Noamesi, B. K. Studies on Cryptolepine. II. Inhibition of Carregeenan Induced Oedema by Cryptolepine. Planta Med. 1981, 41, 392-396.
39. Noamesi, B. K.; Bamgbose, S. O. A. Studies on Cryptolepine. Cryptolepine Antagonism of Noradrenaline and Modification of this Effect by Calcium Ions and Prostaglandin E2 on Rat Isolated Mesenteric Artery. Planta Med. 1983, 47, 100-102.
40. Noamesi, B. K.; Bamgbose, S. O. A. In Proceeding of the First International Symposium on Cryptolepine; Boakye-Yiadom, K., Bamgbose, S. O. A., Eds.; University of Science and Technology: Ghana, 1983; pp 41-51.
41. Raymond-Hamet. Sur les effets hypotenseurs et vaso-dilatateurs de la Cryptolepine. (On the Hypotensive and Vasodilative Effects of Cryptolepine.) Compt. Rend. 1938,207, 1016-1018.
42. Raymond-Hamet. Sur Quelques Propriétés Physiologiques Des Alcaloïdes du Cryptolepis sanguinolenta Schlechter. (On Some Physiological Properties of the Alkaloids of Cryptolepis sanguinolenta Schlechter.) Compt. Rend. Soc. Biol. 1937,126, 768770.
43. Rauwald, H. W.; Kober, M.; Mutschler, E.; Lambrecht, G. Cryptolepis sanguinolenta: Antimuscarinic Properties of Cryptolepine and the Alkaloid Fraction at Ml, M2, and M3 Receptors. Planta Med. 1992, 58, 486-488.
44. Oyekan, A. O.; Okafor, J. P. O. Effects of Cryptolepine Alone and in Combination with Dipyridamole on a Mouse Model of Arterial Thrombosis. J. Ethnopharmacol. 1989, 27, 141-148.
45. Oyekan, A. O.; Botting, J. H.; Noamesi, B. K. Cryptolepine Inhibits Platelet Aggregation In vitro and In vivo and Stimulated Fibrinolysis Ex vivo. Gen. Pharmacol. 1988, 19, 233-237.
46. 2+. Gen. Pharmacol. 1993, 24, 461-469.
47. Oyekan, A. O.; Ablordeppey, S. Y. Effects of Cryptolepine on Collagen-Induced Aggregation and on the Mobilization and Metabolism of Arachidonic Acid by Rabbit Platelets. Gen. Pharmacol. 1993, 24, 1285-1290.
48. Noamesi, B. K; Bamgbose, S. O. A. The Alpha-Adrenoceptor Blocking Properties of Cryptolepine on the Rat Isolated Vas Deferens. Studies on Cryptolepine (1). Planta Med. 1980, 39, 51-56.
49. Oyekan, A. O. Role of the Endothelium and Cyclic GMP in Renal Vasodilator Responses to Cryptolepine in Rats. J. Cardiovasc. Pharmacol. 1994, 23, 602-611.
50. Noamesi, B. K.; Paine, A.; Kirby, G. C.; Warhurst, D. C.; Phillipson, J. D. In Vitro Antimalarial Activity of Cryptolepine, an Indoloquinoline. Trans. R. Soc. Trop. Med. Hyg. 1991, 85, 315.
51. Kirby, G. C.; Paine, A.; Warhurst, D. C.; Noamese, B. K.; Phillipson, J. D. In vitro and in vivo Antimalarial Activity of Cryptolepine, a Plant-derived Indoloquinoline. Phytother. Res. 1995, 9, 359-363.
52. Wright, C. W.; Phillipson, J. D.; Awe, S. O.; Kirby, G. C.; Warhurst, D. C.; Quetin-Leclerq, J.; Angenot, L. Antimalarial Activity of Cryptolepine and Some Other Anhydronium Bases. Phytother. Res. 1996, 10, 361-363.
53. 3H-Cryptolepine in Mice. Arch. Int. Pharmacodyn. 1991, 373, 5-14.
54. Tackie, A.; Schiff, P.; Sharaf, M. PCT International Application WO 94/18203. This application also describes a novel alkaloid \viih antimalarial activity.
55. Paulo, A.; Gomes, E. T.; Houghton, P. J. J. New Alkaloids From Cryptolepis sanguinolenta. J. Nat. Prod. 1995, 58, 1485-1491.
56. Tackie, A. N.; Sharaf, M. H. M.; Schiff, P. L., Jr.; Boye, G. L.; Crouch, R. C.; Martin, G. E. Assignment of the Proton and Carbon NMR Spectra of the Indoloquinoline Alkaloid Cryptolepine. J. Heterocycl. Chem. 1991, 28, 1429-1435.
57. Holt, J. S.; Petrow, V. Carbazoles, Carbolines, and Related Compounds. Part I. Quindoline Derivatives. J. Chem. Soc. 1947, 607-611.
58. Deguitis, Yu. A.; Ezyarskaite, A. B. Alkylation of Quindoline and Quindoline-11-Carboxylic Acid. Khim. Geterotsikl. Soedin. 1986, 1375-1379.
59. This procedure does not work with chloroform that has been stablized with ethanol.
60. Frost, S. C.; Lane, M. D. Evidence for the Involvement of Vicinal Sulfhydryl Groups in Insulin-activated Hexose Transport by 3T3-L1 Adipocytes. J. Biol. Chem. 1985, 260, 2646-2652.
61. Further studies designed to differentiate Cryptolepine hydrochloride's glucose-lowering ability and an anorexigenic effect will be published separately; see ref 19.
62. Dubenko, L. G.; Gerber, R. E.; Litvak, J.; Peterli-Roth, P; Sloan, B.; Luo, J.; Reed, M. J.; Cooper, R.; Bierer, D. E. Antihyperglycemic Activities of Cryptolepine Analogues: An Ethnobotanical Lead Structure Isolated from Cryptolepis Sanquinolenta. Presented at the 213th National ACS Meeting in San Francisco, CA, April 13, 1997; MED132; J. Med. Chem., in review.
63. Moran, K. In Biodiversity and Human Health; Grifo, F., Rosenthal, J., Eds.; Island Press: Washington, DC, 1997; pp 243-263.